In patients with DM and HFpEF, treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin resulted in significant downregulation of miR-126, miR-342-3p, and miR-638. This evidence concerns the gene SLC5A2 and diabetes mellitus.